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An increased intake of Zinc (Zn) may reduce the risk of degenerative diseases but may prove 
to be toxic if taken in excess. This study aimed to investigate whether Zinc carnosine 
supplement can improve Zn status, genome stability events and Zn transporter gene 
expression in an elderly (65-85y) South Australian cohort with low plasma Zn levels.  
 
Methods and results: 
A 12 week placebo-controlled intervention trial was performed with 84 volunteers 
completing the study, (Placebo, n=42) and (Zn group, n=42). Plasma Zn was significantly 
increased (p<0.05) by 5.69% in the Zn supplemented group after 12 weeks. A significant 
(p<0.05) decrease in the micronucleus frequency (-24.18%) was observed for the Zn 
supplemented cohort relative to baseline compared to the placebo group. Reductions of -
7.09% for tail moment and -8.76% for tail intensity were observed for the Zn group (relative 
to baseline) (p<0.05). Telomere base damage was found to be also significantly decreased in 
the Zn group (p<0.05). Both MT1A and ZIP1 expression showed a significant increase in the 
Zn supplemented group (p<0.05).  
 
Conclusion: 
Zn supplementation may have a beneficial effect in an elderly population with low Zn levels 
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1.0 Introduction 
It is known that more than 100 specific enzymes require Zn for their catalytic function 
emphasising the critical role played by Zn in cellular processes including genomic stability 
events [1]. Previous evidence has shown genomic instability events as being associated with 
increased cancer risk [2, 3]. The fact that Zn is required as a cofactor in DNA metabolism, is 
suggestive that deficiency in this micronutrient may induce important chromosomal 
mutations that increase cancer risk. Several studies show that Zn deficiency causes DNA 
oxidation, DNA breaks and chromosome damage [4-6].  
Mild Zn deficiency has been reported in apparently normal ageing, older individuals  with 
gastrointestinal problems, individuals with compromised immune function and in vegetarians 
[7]. Ageing populations are at risk of Zn deficiency because of numerous factors such as 
those reported by the International Zn Nutrition Consultative Steering Committee (2004) [8]. 
Zn deficiency has been shown to be prevalent in a number of studies investigating Zn status 
in elderly populations [9-11]. Deficiency of Zn may cause impaired immune function [12-
14], delayed wound healing [15], depression [16], impaired cognitive function [17] and 
increased oxidative stress [18, 19]. As Zn deficiency may have serious implications for the 
health of ageing individuals, it is important to maintain adequate Zn nutriture within this 
population.  
 
In 2004, the ZnAge project investigated various health-related impacts of Zn 
supplementation among the elderly in European countries [16, 18, 20-24]. Putics et al (2008) 
concluded that proper dietary Zn may have an important role in anti-aging mechanisms 
involving the immune system [24].  A further report showed that Zn supplementation reduces 
spontaneous inflammatory cytokine release and restores T cell function [25]. Marcellini et al 
(2008) showed that Zn supplementation given to the elderly in the ZnAge project affected 
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psychological dimensions dependent on IL-6-174G/C polymorphism [20]. Despite these 
findings knowledge gaps remain regarding the effect of Zn supplementation in relation to 
genomic stability and integrity in an elderly population.  
The aim of this study was to investigate whether taking a daily supplement of 20 mg of 
Zn can improve Zn status, genome stability events and Zn transporter gene expression in an 
elderly (65-85y) South Australian cohort characterised by having low plasma Zn levels 
(<0.77 mg/L;11.7 µM). 
2.0 Materials and methods 
2.1 Screening and recruitment of volunteers 
Volunteers were recruited through the CSIRO Clinical Research Unit database and by 
advertising in local newspapers. The volunteers did not receive any remuneration for their 
participation. In this study individuals were excluded if 1) supplementing with more than 
25% of the recommended dietary intake of Zn, 2) had a habitual dietary Zn intake > 20 
mg/day, 3) were undergoing radiotherapy/chemotherapy treatment for cancer and d) had 
plasma Zn levels > 0.77 mg/L. A total of 208 volunteers aged 65-85 years old met the 
selection criteria and were screened for plasma Zn status using a non-fasted blood sample 
collected in the morning in a lithium heparin tube. Those with plasma Zn concentration ≤ 
10.0 µM (≤ 0.65 mg/L - cut-off point for Zn deficiency [26]) were given priority for inclusion 
in the study. As there were too few individuals with plasma Zn ≤ 0.65 mg/L (10.0 µM), we 
eventually selected all those with plasma Zn status < 0.77 mg/L (11.77 µM) (n=90) and the 
volunteers were consented to participate in the study. Body Mass Index was measured and 
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2.2 Intervention design 
The study was designed as a randomised, placebo-controlled intervention in a free-living 
elderly, healthy population. This study was approved by the Human Research Ethics 
Committee of the CSIRO Food and Nutrition (09/25), University of Adelaide Ethics 
Committee and Australian New Zealand Clinical Trial Registry (ACTRN: 
ACTRN12610000059066). Volunteers with low plasma Zn (< 0.77 mg/L;11.7 µM) were 
randomised into two groups; placebo and Zn supplemented group.  
The Zn supplement tablet used in this trial is a commercially available Zn carnosine 
chelate supplement, which was supplied and prepared by Metagenics (Queensland, 
Australia). Each Zn carnosine supplement tablet contained 86.9 mg of Zn carnosine with 
maltodextrin as excipient. The placebo tablet was 100% pure maltodextrin. The Zn dose in 
each supplement tablet was 20 mg/day which is within the safe physiological range [8]. The 
placebo group received an identical tablet, which only contained the excipient maltodextrin. 
The volunteers consumed one tablet (Placebo or Zn carnosine) per day.   
2.3 Nutritional assessment 
A nutrition survey was carried out to investigate the estimated dietary intake of Zn in the 
study cohort. The volunteers who participated in the study were required to complete the 
validated Anti-Cancer Council of Victoria (ACCV) Food Frequency Questionnaire at the 
start of the study [27] and analysed with  NUTTAB95 nutrient composition data [27].  
2.4 Blood collection and sample preparation 
For screening, one tube (5 ml) of non-fasted blood per volunteer was collected in a lithium-
heparin vacutainer (Vacuette, Austria). During the intervention, at baseline and 12 weeks, 
three tubes of blood (6-8 ml for each) were collected in the morning after an overnight fast 
into a potassium-EDTA tube for homocysteine (Hcy) measurement, and another two lithium-
heparin tubes for all other assays.  
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a) Plasma Isolation 
Blood was spun at 3000 rpm for 20 minutes at 4°C and plasma was transferred into new tubes 
according to the assays to be investigated. Spare plasma was labelled and kept at -80°C. 
b) Isolation and storage of lymphocytes 
Lymphocytes were isolated using Ficoll-Paque™ (Amersham Pharmacia Biotech).  For 
the Cytokinesis block micronucleus cytome (CBMN Cyt) assay, a total cell count was 
performed and 750 µl cultures were set up at 1x10
6
 /ml, in duplicate. Cultures were placed in 
an incubator at 37°C with 5% CO2 until ready for phytohaemagglutinin (PHA) addition. For 
the alkaline comet assay, 500 µl of 1X10
5
 cells/ml suspension was prepared for each 
volunteer. Spare cells were spun down and resuspended in 500 µl PBS with 10% DMSO 
(Sigma, Australia), then stored in -80°C prior to DNA/RNA isolation. The remaining blood 
was collected and transferred into new tubes and kept at -20 °C prior to erythrocyte 
superoxide dismutase measurements. 
2.4.1 Plasma analysis 
a) Plasma mineral, B12, Folate, Homocysteine and Carnosine analysis 
Plasma samples were sent to the Waite Analytical Services (WAS, Adelaide University) for 
plasma Zn and other mineral analysis. A further 300 µl of plasma was transferred to new 
tubes and kept at -80°C before being sent to the Institute of Medical and Veterinary Science 
(IMVS) for vitamin B12 and folate analysis. The concentration of plasma Zn and other 
minerals (Iron, Copper, Calcium, Magnesium, Sodium, Potassium, Phosphorus, Sulphur) was 
determined by Inductively Coupled Plasma Optical Emission Spectrometry (ICPOES, 
Agilent Technologies 7500c, Japan), following digestion with nitric acid and hydrochloric 
acid. Plasma Carnosine was measured using an ELISA antibody kit (USCN Life Science, 
USA). 
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b) Ferric Reducing Ability of Plasma (FRAP) analysis  
The FRAP assay was used to measure the combined antioxidant effect of the non-enzymatic 
defences in plasma samples [28]. The absorbance of the products of the FRAP reaction was 
measured on an ELISA microplate reader (SpectraMax 250, Molecular Devices, CA, USA) at 
a wavelength of 593 nm. 96 well plates were used in this assay for multiple readings as only 
300 µl solution was used for absorption readings. 
     c) eSOD assay 
For this analysis, we used the SOD assay kit (Trevigen Inc, USA). A standard curve 
to verify that the assay is working predictably and that concentration dose-response is linear 
within the relevant range was established prior to analysis of samples  
2.4.2 DNA Damage assays 
a) CBMN-Cyt assay 
Following Cyto-B treatment, cells are harvested following a well validated protocol onto 
slides by cytocentrifugation, stained and scored for chromosomal damage biomarkers using 
light microscopy [29].  500 cells were scored to determine the frequency of necrotic, 
apoptotic, mono-, bi- and multi-nucleated cells and nuclear division index (NDI). 1000 
binucleated cells were scored to determine the frequency of chromosomal DNA damage 
biomarkers including micronuclei (MNi), nucleoplasmic bridges (NPB) and nuclear buds 
(NBUDs).   
b) Alkaline comet assay 
Single cell gel electrophoresis (comet assay) was used to measure DNA strand breaks and 
alkaline labile sites in lymphocytes. The assay was conducted under alkaline conditions as 
previously described [30, 31] with slight modification for use with a high throughput 
CometSlide HT (Trevigen Inc. Cat 4252-02K-01). 100 cells were randomly selected from 
each spot and scored with online software (Tritek - http://autocomet.com/main_home.php) 
for tail moment and tail intensity. Tail moment (tail length X DNA density) and tail intensity 
(% DNA in tail) were used as indicators of DNA damage.  
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2.3.3 Isolation of DNA/RNA 
DNA and RNA were isolated from lymphocytes using TRIzol (Ambion). A 0.5 ml volume of 
trizol was used to homogenise each sample. The only alteration from the manufacturer’s 
directions was the use of 2 µg/ml glycogen (Ambion) and 5 mM sodium acetate to aid RNA 
precipitation.  
a) Telomere length 
A quantitative real-time polymerase chain reaction (qPCR) based method was used to 
measure absolute telomere length (aTL). This method is based on the Cawthon method for 
relative measurement of telomere length (TL) but modified by introducing an oligomer 
standard to measure aTL and was performed as previously described [32-34]. 
b) Telomere base damage  
Telomere base damage was measured using a qPCR based method [35] to measure the 
amount of oxidised residues as well as other base lesions within telomeric DNA that are 
recognised and excised by the bacterial enzyme, formamidopyrimidine DNA-glycosylase 
(FPG). This method is based on differences in PCR kinetics between the DNA template 
exhaustively digested by FPG and undigested DNA i.e.  ∆CT (CT treated- CT untreated) and 
was performed as previously decribed [35].   
c) MT1A and Zip1 expression 
Gene expression of two different types of Zn transporters, MT1A and Zip1 was measured 
using Taqman quantitative Real-Time PCR (ABI 7500 Fast Sequence Detection system, 
Applied Biosystems) in the isolated RNA from lymphocytes. Inventoried Taqman gene 
expression assays and one custom-designed assay were obtained for Zip1(Hs00205358_m1) 
and MT1A (Hs00831826_s1) mRNA. All samples were quantified in duplicate, using the 
comparative CT method for relative quantification of gene expression, normalized to 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). All samples were run on an Applied 
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Biosystem 7300 Real Time PCR System and ABI 7300 Sequence Detection System with the 
SDS Ver 1.9 software (Applied Biosystem, Foster City, CA). Cycling conditions were: 10 
minutes at 95°C, followed by 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. The level 
of expression of a specific gene in each sample was quantified by measuring the level of 
fluorescence relative to that of baseline samples.  
2.3.4 Statistical analysis 
With 40 subjects per group, the study had 80% power to detect an increase in plasma Zn of 
0.055 µg/ml and a decrease in micronucleus frequency of 8.30 per 1000 binucleated cells at 
P=0.05 (one-tailed). These power calculations are based on standard deviation values of 
0.095 for plasma Zn and 14.8 for micronucleus frequency in lymphocytes obtained from our 
own database from previous studies on healthy individuals aged 65-85 years. The detectable 
effect size of micronucleus frequency is equivalent to the DNA damage level induced by 0.2 
Gy of X-rays which is a carcinogenic dose [36]. 
Q-Q plots on standard residual of all outcome measures were performed to test the 
normality of the data sets. Comparisons between groups were performed using general linear 
models and having treatment and gender as factors. To compare  the difference in response 
between groups after 12 weeks, the percentage difference relative to baseline values was 
calculated as recommended by Vickers and Altman (2001) [37]. Correlation analysis between 
two sets of data was performed using Pearson’s test and Partial Correlation Test. A value of 
p<0.05 was considered to be statistically significant. Prism 5.0 (GraphPad Inc, San Diego, 
CA, USA) and SPSS for Windows (version 17.0, SPSS Inc, Chicago) software were used to 




www.mnf-journal.com Page 10 Molecular Nutrition & Food Research 
 
This article is protected by copyright. All rights reserved. 
 
3.0 Results 
3.1 Characteristics of the volunteers 
A total of 208 volunteers aged 65-85 years old met the selection criteria and were screened 
for plasma Zn status. Those with plasma Zn concentration ≤ 10.0 µM (≤ 0.65 mg/L - cut-off 
point for Zn deficiency [26]) were given priority for inclusion in the study. As there were too 
few individuals with plasma Zn ≤ 0.65 mg/L (10.0 µM), the cut-off point was increased and 
eventually selected all those with plasma Zn status < 0.77 mg/L (11.77 µM) (n=90) and the 
volunteers were then consented to participate in the study. The volunteers were then 
randomly distributed into two groups (Zn supplement vs placebo). 42 out of 45 participants 
from each group completed the intervention. Reasons for drop-out during the trial included 
overseas travel (n=2), noncompliance (n=2), adverse events (n=1) and voluntary withdrawal 
(n=1). Age (Placebo group: 73.12 ± 5.19 years; Zn group: 73.88 ± 4.99 years), BMI (Placebo 
group: 26.73 ± 4.29 kg/m
2
; Zn group: 26.81 ± 4.07 kg/m
2
) and the estimated dietary Zn 
intake (Placebo group: 10.58 ± 3.62; Zn group: 10.97 ± 3.91 mg/day) was not significantly 
different between placebo and Zn groups, respectively (Supp Table 1). However, plasma Zn 
values at screening were marginally but significantly lower in the placebo group (0.69 ± 0.06 
mg/L) compared to the Zn group (0.71 ± 0.04 mg/L). Compliance rate was high (>98%) with 
respect to tablet consumption in both groups.  
3.3 Plasma micronutrients: Zinc, Carnosine, Mineral, B12, Folate and Homocysteine 
At baseline, no difference between groups was observed, but significant change was found at 
the end of 12 weeks intervention. In the placebo group, plasma Zn showed a significant drop 
of -4.48% after 12 weeks of intervention from 0.905 ± 0.099 mg/L (13.84 ± 1.51 µM) to 
0.863 ± 0.080 mg/L (13.19 ± 1.22 µM). However, in the Zn group,  plasma Zn was 
significantly increased  by 5.69% after 12 weeks of intervention from 0.926 ± 0.096 mg/L 
(14.16 ± 1.46 µM) to 0.972 ± 0.135 mg/L (14.86 ± 2.06 µM) (Table 1). Despite the changes 
in plasma Zn concentration, there was no significant increase in the carnosine concentration 
in the group consuming the Zn carnosine supplement (Table 2).  
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No significant changes were observed between both groups following intervention for 
other minerals such as iron, copper, potassium, sodium, magnesium and phosphorus as well 
as vitamin B12, folate and homocysteine except for calcium, and sulphur levels (Table 1 and 
2). However, within groups, a significant increase of 92.36 ± 3.77 to 95.56 ± 3.61 mg/L in the 
Placebo group and 92.86 ± 3.66 to 97.75 ± 3.69 mg/L in the Zn group were observed for 
calcium in plasma (p<0.05). For magnesium, an increase from 20.08 ± 1.61 to 20.58 ± 1.49 
mg/L was observed in the Placebo group while a significant increase of 5.7% (relative to 
baseline) was observed in the Zn group (baseline: 19.49 ± 1.76; 12 weeks: 20.61 ± 1.51 
mg/L). Plasma folate showed a significant increase in the Zn group from baseline levels at 
33.50 ± 7.81 to 35.88 ± 8.81 nmol/L at the end of the 12 week intervention (Table 2). 
 
3.4 Antioxidant activity (FRAP and eSOD) 
 
Antioxidant activity measured via FRAP was significantly increased in the Zn group 
following 12 weeks of supplementation (p<0.05) from 1180.62 ± 315.40 to 1447.79 ± 471.58 
µmol/L (Table 2). However, no significant difference between groups was observed 
following the intervention. eSOD which reflects Cu-Zn SOD activity in erythrocytes was also 
significantly increased in the Zn group following the 12 week intervention and the changes 
were significant between groups (p<0.05). eSOD showed a 33.07% increment (relative to 
baseline) in the Zn group, compared to the Placebo group which showed only 2.45% 
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3.5 DNA damage assays: CBMN-Cyt assay and alkaline comet assay 
The CBMN-Cyt assay results (Table 3), showed a significant decrease in the frequency of 
MNi for the Zn group following supplementation (p<0.05). The reduction of 24.18% 
(relative to baseline) was statistically significant compared to the placebo group which 
showed an increase of 1.77% (Fig 3). There were no significant changes in the frequency of 
NPB and NBUD for both groups. Both tended to decrease in the Zn supplemented group but 
the changes were not significant. Necrotic cells were higher in the placebo group following 
12 weeks intervention with a significant increase of 44.28% (relative to baseline). However, 
no change was observed in the percentage of necrotic cells in the Zn supplemented group 
with only an 18.21% increase relative to baseline. Apoptotic cells were decreased in the Zn 
group (p<0.05) following the duration of intervention with a reduction of 7.53% relative to 
baseline. NDI was increased in both groups following the 12 weeks of intervention (p<0.05) 
(Table 3) but no significant change between groups was observed. 
 
 The comet assay results showed a significant effect of time and treatment of Zn 
supplementation for both tail moment and tail intensity (p<0.05) (Table 3). Tail moment for 
the placebo group increased from 0.499 ± 0.286 to 0.809 ± 0.354 after 12 weeks of 
intervention and tail intensity values were also increased from 4.301 ± 1.306 to 5.139 ± 
1.953. For the Zn group, both tail moment and tail intensity values were decreased following 
12 weeks intervention (Tail moment-baseline: 0.476 ± 0.210; 12 weeks: 0.376 ± 0.229; Tail 
intensity-baseline: 4.700 ± 1.365; 12 weeks: 2.985 ± 1.587). Reductions of 7.53% for tail 
moment and 8.76% for tail intensity were observed for the Zn group (relative to baseline) 
(Fig 4). Tail moment and tail intensity in the Placebo group showed a significant 141.6% and 
28.95% increase respectively relative to baseline (p<0.05).  
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3.6 Telomere integrity: Telomere length and telomere base damage             
 
Telomere length was found to be shorter in the Zn supplemented group following the 12 
week intervention but the difference was not significant relative to the Placebo group. Both 
groups showed a significant increase in telomere length within groups following 12 weeks of 
intervention with an increment of 9.65% for the Zn supplemented group and 10.36% for the 
Placebo group (relative to baseline) (Fig 5). Telomere base damage was found to be 
significantly decreased in the Zn group (p<0.05) (Baseline: 13.88 ± 18.04, 12 weeks: 6.82 ± 
15.18 [8 oxodG/kb telomere]), but no difference was observed between groups.  
3.7 Zinc transporter genes: MT1A and ZIP1 
MT1A and ZIP1 were measured as biomarkers for Zn status and Zn transportation. Both 
MT1A and ZIP1 expression showed a significant increase in the Zn supplemented group 
compared to the Placebo group (p<0.05) (Table 3). MT1A expression was significantly 
higher in the Zn supplemented group (p<0.05) following the 12 week intervention compared 
to the Placebo group (Placebo: 5.29 ± 5.86, Zn: 8.46 ± 4.69 arbitrary unit). ZIP1 expression 
showed a 19.09% increase relative to the baseline measure, compared to a 9.38% increase in 
the Placebo group (Fig 6).  
3.8 Correlation between plasma Zinc and other measured biomarkers  
Pearson correlation analysis of the relationship between plasma Zn (at the baseline and at the 
end of the study) with other biomarkers was performed (Supporting Information Table 2). At 
baseline, no correlation between plasma Zn and other plasma and DNA damage biomarkers 
was observed. However, at the end of 12 weeks of supplementation, plasma Zn was 
significantly correlated with eSOD (r=0.279, p=0.010), tail moment (r=-0.219, p=0.045) and 
micronuclei (r=-0.235, p=0.032) (Supporting InformationTable 2). 
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 Partial correlation analysis of the relationships between plasma Zn (at the start and at 
the end of the trial), after controlling for age and gender, and all biomarkers in this study was 
also performed. At baseline, no correlation between plasma Zn and other plasma and DNA 
damage biomarkers was observed. At the end of 12 weeks of supplementation, plasma Zn 
was found to be correlated only with ZIP1 expression (r=0.576, p=0.039) (Supporting 
Information Table 3).  
3.8 Correlation between other measured biomarkers  
Based on the partial correlation, at baseline, vitamin B12 was correlated with folate (r=0.221, 
p=0.047) and Hcy was negatively correlated with B12 (r= -0.438, p=0.000) and folate (r= -
0.221, p=0.048). FRAP values were negatively correlated with MT1A gene expression (r=-
0.259, p=0.019) and carnosine concentration was negatively correlated with Hcy (r=-0.293, 
p=0.008). For DNA damage events, tail intensity values was positively correlated with 
telomere length (r=0.264, p=0.017) and negatively correlated with carnosine concentration 
r=-0.236, p=0.034). Necrosis was negatively correlated with folate concentration (r=-0.241, 
p=0.030) and significantly correlated with ZIP1 expression (r=0.322, p=0.003) and eSOD 
levels (r=0.222, p=0.046). Apoptosis was also correlated with ZIP1 expression (r=0.265, 
p=0.017) and necrosis (r=0.541, p=0.000). Nuclear Division Index was significantly 
correlated only with apoptosis (r=0.232, p=0.037). Nucleoplasmic bridges was significantly 
correlated with ZIP1 expression (r=0.334, p=0.002), necrosis (r=0.557, p=0.000) and 
apoptosis (r=0.530, p=0.000). There were more significant correlations observed for nuclear 
buds. Nuclear bud frequency was significantly correlated with ZIP1 expression (r=0.274, 
p=0.013), necrosis (r=0.451, p=0.000), apoptosis (r=0.401, p=0.000), micronuclei frequency 
(r=0.259, p=0.020) and nucleoplasmic bridges (r=0.615, p=0.000). 
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 Following 12 weeks intervention, Hcy levels was found to be negatively correlated 
with B12 concentration (r=-0.627, p=0.022). MT1A expression was significantly correlated 
with folate levels (r=0.660, p=0.014). For antioxidant measures, there was no significant 
correlation observed for FRAP values with any of the biomarkers measured in the study 
while eSOD values were found to be negatively correlated with telomere base damage (r=-
0.619, p=0.024). With regards to DNA damage events, tail moment was negatively correlated 
with eSOD values (r=-0.693, p=0.009), while nuclear division index was found to be 
correlated with tail moment (r=0.623, p=0.023) and negatively correlated with necrosis (r=-
0.567, p=0.043). Micronuclei frequency was found to be negatively correlated with telomere 
length (r=-0.567, p=0.043) and carnosine concentration (r=-0.564, p=0.045) but positively 
correlated with nuclear division index (r=0.639, p=0.019). Only one positive correlation was 
found for nucleoplasmic bridges, which was with apoptosis (r=0.572, p=0.041). Nuclear buds 
were found to be negatively correlated with eSOD values (r=-0.588, p=0.035) but positively 
correlated with telomere base damage (r=0.564, p=0.045) and strongly correlated with 




The results of this study show that Zn carnosine supplementation in an elderly population is 
beneficial in reducing the micronucleus frequency measured by the CBMN Cytome assay and 
both tail moment and intensity as measured via the comet assay following 12 weeks of 
intervention. To the authors’ knowledge, this is the first study conducted to investigate the 
impact of Zn supplementation on CBMN Cytome biomarkers and telomere integrity in an 
elderly population.  
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 Plasma Zn at baseline was found to be higher than plasma Zn levels at screening. This 
may possibly be due to the fasting state and diurnal variation as both can affect plasma Zn 
concentrations [8]. Volunteers who were fasting tended to have higher plasma Zn compared 
to non-fasting volunteers [8]. This possibly explains why in our study, a lower plasma Zn was 
observed at screening but the value increased at baseline although they were from the same 
cohort. According to Brown (1998) [38],  in a population aged 22-75 years old, the reference 
value for plasma Zn is 16.6 ± 6.2 µM. The lower limit of fasting plasma Zn levels has been 
recommended at 10.7 µM [39] and therefore the cut-off level below which a Zn-deficient 
status is possible [40]. The cut off point for Zn deficiency was set to 11.6 µM in order to 
obtain 90 people with the lowest Zn status at screening, which was slightly higher than the 
10.7 µM value recommended.  
An increase of 5.40% in plasma Zn after 12 weeks of supplementation in the Zn group 
indicates that daily intake of Zn at 20 mg/day improved Zn status. Savarino et al (2001) [41] 
showed that high plasma  Zn in older individuals may contribute to their longevity. The 
increased plasma Zn levels is in agreement with the beneficial effect of Zn supplementation 
reported in an older institutionalized population presenting a large prevalence of biological 
Zn deficiency (< 10.7 µM) [42].  
In this study, we also measure plasma levels of other minerals to see the changes and 
correlation with plasma Zn and other variables. Calcium and magnesium concentration 
appeared to increase in both the Placebo and Zn groups. This could be explained by the 
excipient maltodextrin in the zinc carnosine and placebo tablets. A recent study in rats 
showed that maltodextrin increased absorption of calcium, magnesium, iron and zinc from 
the diet possibly by increasing bacterial fermentation in caecum [43].  However, in our study 
iron and zinc concentration did not increase in plasma which suggests that the effects of 
maltodextrin on mineral absorption in humans may be limited to calcium and magnesium. 
Further studies in humans are required to test this hypothesis. 
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Concentration of plasma B12, folate and Hcy were also measured as these may affect 
DNA damage and telomere maintenance [44-46]. It was found that Zn supplementation did 
not alter plasma B12, folate and Hcy substantially although a trend for increased plasma 
folate in the Zn group was evident. These results are in agreement with a previous study by 
Ducros et al 2009 [47] that showed after six months of intervention with Zn at 15 mg/day and 
30 mg/day, there was no effect on Hcy, B12 and folate levels. It is evident that the extent of 
Zn deficiency in our cohort was not sufficient to substantially alter plasma B12 and Hcy 
levels in plasma and Zn supplementation may have contributed marginally to improved folate 
concentration in plasma.  
The impact of Zn supplementation in relation to the antioxidant profile (FRAP and 
eSOD) of the participants was also investigated.  It was shown that FRAP and eSOD were 
increased following Zn supplementation.  This result is similar to a previous study that 
reported Zn supplementation increased the eSOD activity following both 3 and 6 month 
interventions [48]. However, in the same study, an increase in FRAP was not found. This 
negative result following Zn supplementation may have been because only 4.8% were 
middle-aged and 5.6% were older subjects that were below the cut off level for biological Zn 
deficiency (10.7 µM) [48]. In another study, Song et al [49] found that FRAP activity was 
unaffected following Zn supplementation while eSOD tended to decrease after marginal Zn 
depletion and increased after Zn repletion, but the changes were not statistically significant.  
 To our knowledge, this is the first study to investigate the effect of Zn 
supplementation on genome stability in an elderly South Australian population. A reduction 
in the micronucleus frequency was observed together with both tail moment and tail intensity 
as measured via the alkaline comet assay following 12 weeks intervention with Zn at 20 
mg/day.  A previous study in rats has shown that severe Zn depletion caused an increase in 
DNA damage in peripheral blood cells compared to Zn replete controls and this was 
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associated with impairment in DNA repair, compromised p53 DNA binding, and 
upregulation of the base excision repair (BER) proteins, OGG1 and PARP [50]. A further 
study conducted in rats showed that marginal Zn deficiency (MZnD) caused an  increase in 
oxidative DNA damage in the prostate after chronic exercise [51]. Dietary Zn restriction and 
repletion of Zn to its normal status was found to affect DNA integrity in healthy men aged 
19-50 years old [49]. Plasma Zn concentrations showed a negative correlation with DNA 
damage measures as measured via the alkaline comet assay (r=-0.47, p=0.014) in agreement 
with our study [49].  
Zinc carnosine at optimal concentration in cells was shown to have an impact on Zn 
status and to have lower DNA damage events as measured via CBMN Cytome assay as well 
as following induced damage [52-54]. Activation of MT and SOD was predicted to be key 
components in this effect as measured via protein expression, in addition to activation of 
PARP and OGG1 [54]. This is in line with our results that observed an increase in eSOD 
following Zn supplementation. In addition, Zn is an essential component for PARP-1, which 
binds via its Zn domain to DNA strand breaks and thereby assisting in the recruitment of 
DNA repair complexes [55]. Positive correlation between cellular poly(ADP-ribosyl)ation 
and Zn status in human peripheral blood mononuclear cells was reported previously [56], 
indicating that Zn plays an important role in maintaining genomic stability [5]. Besides, Zn is 
also part of OGG1 which is another DNA repair enzyme that is involved in base excision 
repair by removing of 8-hydroxyl-2'-deoxyguanosine, one of the more prevalent oxidative 
DNA damage events [57]. 
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These studies suggest that Zn deficiency may lead to an increase in DNA damage and in 
our study it was shown that Zn supplementation may be beneficial in lowering DNA damage 
especially DNA strand breaks and the frequency of micronuclei. In this study, Zn carnosine  
was used and it has been shown that carnosine is a potent antioxidant [58] and may have an 
impact on DNA damage. The levels of carnosine were very low and did not change 
significantly in the treatment group versus the placebo. However, plasma carnosine was 
inversely correlated with micronuclei at week 12 (r=-0.564) but not at baseline, and inversely 
with comet tail intensity at baseline (r=-0.236) but not at week 12. This suggests that the 
possibility that significant changes in carnosine concentration in blood may affect genome 
stability in lymphocytes cannot be disregarded. 
The relationship between Zn status and telomere biology is not clearly defined. 
Accelerated telomere shortening may result in a DNA damage response leading to 
chromosomal end-to-end fusions, cell arrest and apoptosis [44, 59, 60].  No difference in 
telomere length and telomere base damage between the placebo and Zn treatment group was 
observed in this current study. However, telomere length was observed to increase and 
telomere base damage decreased in the Zn supplemented group when week 12 data was 
compared to baseline. This suggests that the effects are small or a larger study is required to 
achieve statistically significant time and treatment interaction. There are actually very few 
studies that have investigated the impact of Zn on maintaining telomere integrity. Liu and 
colleagues (2004) found that Zn sulphate at 80 µM accelerated telomere loss in hepatoma 
cells (SMMC-7721) after 4 weeks of treatment [61]. Cells with short telomeres are associated 
with impaired Zn homeostasis in hypertensive patients [62].  
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In this study, we focused on the measurement of main Zn transporter for human which are 
MT1A and ZIP1. Gene expression analysis showed that Zn supplementation over 12 weeks 
of intervention increased both MT1A and ZIP1 expression significantly. These genes were 
selected because both are expected to be responsive to Zn concentration because of their 
important role in Zn transport and Zn storage [1, 63]. MT has been found to affect the release 
of Zn for the activity of PARP-1, which is involved in base excision DNA-repair [64]. 
Previous studies have shown that Zn and metallothionein are genome-protective against the 
insults associated with oxidative stress [65-67]. In our study, MT expression was increased in 
the Zn group which may explain the reductions in both tail moment and tail intensity 
observed in the comet assay and also the frequency of micronuclei.  
 
In particular, polymorphisms of the metallothionein gene MT1A were found to influence 
the efficacy of Zn supplementation [21, 23]. As MT induction and expression is mediated by 
IL-6, a multifunctional cytokine which regulates the differentiation and activity of different 
cell types, stress reactions and inflammatory responses [21, 23, 68-70]. Several studies 
suggest that the common IL-6-174 G/C and MT1A +647 polymorphisms interactively affect 
Zn bioavailability and bioefficacy and are likely to be a useful indicator for the selection of 
elderly people who would benefit from Zn supplementation [21-23, 70-72]. It would be of 
interest for future studies to investigate whether polymorphisms in ZnT, ZIP, MT1A and IL6 
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The results from this study show that Zn supplementation in an elderly populations with 
low Zn status can (a) improve Zn status, (b) lower DNA damage events, hence improving 
genome stability, (c) increase antioxidant activity which may lower DNA damage risk [6], 
and (d) increase Zn storage and transporter gene expression (MT1A and ZIP1). Given that 
there is some evidence that the benefits and/or adverse effects of Zn supplementation may 
depend on genotype variations e.g. (MT1A) [18, 20, 23], it will be necessary to find out in 
future whether there are specific genotypes or polymorphisms in genes in high susceptibility 
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Figure 1: Percentage change in Plasma Zn at 12 weeks relative to baseline. Percentage 
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Figure 2: Percentage change in A) Plasma FRAP and B) eSOD, at 12 weeks relative to 
baseline. Percentage change was adjusted for baseline values. FRAP – Ferric Reducing 
Activity in Plasma; eSOD – erythrocytes Superoxide Dismutase.  
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Figure 3: Percentage change in A) necrotic cells and B) micronuclei frequency at 12 
weeks relative to baseline. Percentage change was adjusted for baseline values. Mean values 
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Figure 4: Percentage change in A) tail moment and B) tail intensity at 12 weeks relative 
to baseline. Percentage change was adjusted for baseline values. Zn and Mean values with * 
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Figure 5: Percentage change in A) telomere base damage and B) telomere length at 12 
weeks relative to baseline. Percentage change was adjusted for baseline values.  
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Figure 6: Percentage change in A) MT1A and, B) ZIP1 gene expression at 12 weeks 
relative to baseline. Percentage change was adjusted for baseline values. Mean values with * 
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Table 1: Comparison of plasma mineral, B12, Folate, Homocysteine, plasma Carnosine, plasma FRAP and eSOD during the stages of the 
intervention within and between groups. Values are represented as mean ± SD. Mean values were significantly different for comparison *P<0.05, 
**P<0.01. † p value for comparison between groups at baseline and at week 12 ;‡ p value for comparison between baseline and week 12 within the Placebo 
or Zn group. 
 
 Placebo (n=42) Zn (n=42) P value † 
Baseline 12 weeks Baseline 12 weeks 
Plasma Mineral (mg/L) 
Zinc (Zn) 0.905 ± 0.099 0.863 ± 0.088 0.926 ± 0.096 0.972 ± 0.135 Baseline : 0.340 
Week 12 : 0.001** 
P value ‡ 0.028* 0.016*  
Iron (Fe) 1.276 ± 0.977 1.079 ± 0.412 1.231 ± 0.414 1.198 ± 0.487 Baseline : 0.838 
Week 12 : 0.106 
P value ‡ 0.142 0.827  
Copper (Cu) 1.197 ± 0.237 1.195 ± 0.232 1.154 ± 0.191 1.160 ± 0.196 Baseline : 0.138 
Week 12 : 0.208 
P value ‡ 0.842 0.614  
Calcium (Ca) 92.363 ± 3.772 95.557 ± 3.608 92.859 ± 3.661 97.748 ± 3.690 Baseline : 0.551 
Week 12 : 0.009** 
P value ‡   0.001** 0.001**  
Magnesium (Mg) 20.079 ± 1.611 20.575 ± 1.493 19.489 ± 1.762 20.613 ± 1.514 Baseline : 0.120 
Week 12 : 0.911 
P value ‡ 0.005** 0.001**  
Sodium (Na) 3256.250 ± 121.379 3225.529 ± 77.144 3260.641 ± 85.404 3254.611 ± 79.543 Baseline : 0.756 
Week 12 : 0.050 
P value ‡ 0.097 0.659  
Potassium (K) 150.161 ± 16.860 152.894 ± 15.272 150.196 ± 11.512 156.604 ± 13.614 Baseline : 0.991 
Week 12 : 0.234 
P value ‡                                   0.186 0.002**  
Phosphorus (P) 128.272 ± 18.892 128.744 ± 17.282 132.349 ± 19.108 133.181 ± 18.708 Baseline : 0.895 
Week 12 : 0.765 
P value ‡                                  0.889 0.645  
Sulphur (S) 1165.337 ± 66.558 1148.990 ± 55.597 1176.922 ± 61.243 1182.654 ± 58.724 Baseline : 0.369 
Week 12 : 0.004** 
P value ‡                                  0.049* 0.543  
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Table 2: Comparison of B12, Folate, Homocysteine, plasma Carnosine, plasma FRAP and eSOD during the stages of the intervention 
within and between groups. Values are represented as mean ± SD. FRAP – Ferric Reducing Ability of Plasma, eSOD – erythrocyte Superoxide 
Dismutase. Mean values were significantly different for comparison *P<0.05, **P<0.01.  
† p value for comparison between groups at baseline and at week 12  
‡ p value for comparison between baseline and week 12 within the Placebo or Zn group 
 
 Placebo (n=42) Zn (n=42) P value † 
Baseline 12 weeks Baseline 12 weeks 
Plasma B12 (nmol/L) 383.065 ± 274.343 392.286 ± 283.529  305.906 ± 105.830 300.835 ± 102.408 Baseline : 0.084 
Week 12 : 0.052 
                                 0.441 0.611  
Plasma Folate (nmol/L) 33.639 ± 7.628 33.821 ± 7.691 33.500 ± 7.812 35.882 ± 8.818 Baseline : 0.741 
Week 12 : 0.244 
P value ‡ 0.905 0.024*  
Plasma Homocysteine 
(µmol/L) 
11.389 ± 3.014 11.476 ± 3.049 11.393 ± 2.801 11.623 ± 2.468 Baseline : 0.797 
Week 12 : 0.582 
P value ‡ 0.851 0.237  
FRAP (µmol/L) 1216.589 ± 326.284  1311.345 ± 418.126 1180.622 ± 315.404 
 
1447.799 ± 471.582 Baseline : 0.610 
Week 12 : 0.167 
P value ‡ 0.155 0.001**   
eSOD (U/g Hb) 2920.93 ± 330.2 2980.615 ± 275.645 2807.957 ± 571.478 3190.228 ± 374.159 Baseline : 0.780 
Week 12 : 0.005** 
P value ‡ 0.452 0.001**  
Plasma carnosine 
(µmol/L) 
0.664 ± 0.405 0.688 ± 0.382 0.682 ± 0.382 0.739 ± 0.444 Baseline : 0.972 
Week 12 : 0.621 
P value ‡ 0.969  0.936  
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Table 3: Comparison of DNA damage biomarkers, DNA stability biomarkers (CBMN-Cyt, Comet and Telomere assays and gene 
expression (MT1A and ZIP1) during the stages of the intervention within and between groups. Values are represented as mean ± SD. BN – 
binucleates, MNi – Micronuclei, NPB – Nucleoplasmic Bridges, NBuds – Nuclear Buds, kb – kilobase, 8-oxodG - 8-Oxo-2'-deoxyguanosine. 
Mean values were significantly different for comparison *P<0.05, **P<0.01 
† p value for comparison between groups for baseline and week 12  
‡ p value for comparison between baseline and week 12 within the placebo and Zn group 
 
 Placebo Zn P value † 
Baseline 12 weeks Baseline 12 weeks 
DNA damage 
CBMN-Cyt assay 
MNi (per 1000 BN) 12.058 ± 5.310 11.125 ± 5.475 11.200 ± 5.034 6.930 ± 3.467 Baseline : 0.456 
Week 12 : 0.001** 
P value ‡                           0.270 0.001**  
NPB (per 1000 BN) 7.469 ± 4.741 7.523 ± 3.886 7.818 ± 3.972 7.486 ± 2.556 Baseline : 0.861 
Week 12 : 0.839 
P value ‡                          0.911 0.555  
NBUD (per 1000 BN) 3.244 ± 2.080 3.805 ± 1.968 3.648 ± 2.066 3.405 ± 2.065 Baseline : 0.411 
Week 12 : 0.452 
P value ‡                          0.294 0.553  
Necrosis (%) 8.655 ± 3.302 11.365 ± 4.245 8.755 ± 2.632 9.489 ± 2.835 Baseline : 0.878 
Week 12 : 0.018 
P value ‡                         0.001** 0.275  
 
Apoptosis (%) 3.283 ± 1.216 3.371 ± 1.723 3.748 ± 1.397 2.951 ± 1.359 Baseline : 0.200 
Week 12 : 0.216 
 
  
P value ‡                         0.678                           0.012* 
NDI 1.862 ± 0.165 1.965 ± 0.198 1.877 ± 0.150 1.968 ± 0.222 Baseline : 0.650 
Week 12 : 0.949 
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Tail moment (arbitrary unit) 0.499 ± 0.286 0.809 ± 0.354 0.476 ± 0.210 0.376 ± 0.229 Baseline : 0.686 
Week 12 : 0.001** 
P value ‡ 0.001** 0.100  
Tail intensity (% DNA in tail) 4.301 ± 1.306 5.139 ± 1.953 4.700 ± 1.365 2.985 ± 1.587 Baseline : 0.178 
Week 12 : 0.001** 
P value ‡ 0.011* 0.001**  
 
Telomere Integrity 
Telomere length (kb/diploid 
genome) 
2.878 ± 0.458 3.069 ± 0.463 2.725 ± 0.420 2.929 ± 0.449 Baseline : 0.122 
Week 12 : 0.174 
P value ‡ 0.054 0.035*  
Telomere base damage 
(8-oxodG/kb telomere)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
14.503 ± 14.870 9.937 ± 10.671 13.879 ± 18.036 6.820 ± 15.181 Baseline : 0.867 
Week 12 : 0.291 
P value ‡ 0.096 0.009**  
 
Gene expression 
MT1A (arbitrary units) 4.981 ± 5.371 5.294 ± 5.863 4.287 ± 7.710 8.463 ± 4.697 Baseline : 0.643 
Week 12 : 0.009** 
P value ‡ 0.658 0.004*  
ZIP1 (arbitrary units) 2.693 ± 0.712 2.760 ± 0.663 2.894 ± 0.705 3.197 ± 0.598 Baseline : 0.294 
Week 12 : 0.010* 
P value ‡ 0.543 0.045*  
 
 
